Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Auravax Therapeutics, Inc. Estimated value $750K ($750K obligated). Current period of performance ends Dec 31, 2026. Last award drew 1 bidder. Place of performance: HOUSTON TX. Related solicitation 22-100-SOL-00003.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
Recompete timing
PublicCurrent PoP ends Dec 31, 2026 (95 days remaining). Agencies typically plan 12–18 months ahead — at 3.1 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75A50124C00054? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordAuravax Therapeutics, Inc — $750K obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50124C00054?
75A50124C00054 (Auravax auravax overall objective THIS contract) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $750K, currently held by Auravax Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50124C00054?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50124C00054 to Auravax Therapeutics, Inc (potential $750K).
Who is the incumbent on 75A50124C00054?
Auravax Therapeutics, Inc is the incumbent with $750K across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.
When does Auravax Therapeutics, Inc’s 75A50124C00054 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50124C00054? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.